Trial enrollment completion reduces operational risk but shifts the focus to binary efficacy readouts. The stock will likely trade on sentiment and cash runway until Q1 2027 symptomatic data. Monitor for any equity or debt financing updates given the early-stage biotech capital needs through 2028.
Price Chart
Executive Summary
Annovis Bio announced full enrollment of its pivotal Phase 3 trial (NCT06709014) of buntanetap for early Alzheimer's disease, enrolling 850 patients across 83 US sites — exceeding original projections. The dual-readout trial provides symptomatic data in Q1 2027 and disease-modifying data in Q1 2028, with NDA submissions targeted after each readout. This is an operational milestone that de-risks trial execution but provides no efficacy data, leaving the binary outcome intact.
Key Facts
- Full enrollment of 850 patients in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease, exceeding original projections
- Trial conducted across 83 clinical sites in the US with pTau217-confirmed AD pathology
- 6-month symptomatic top-line data readout expected Q1 2027
- 18-month disease-modifying top-line data readout expected Q1 2028
- Company preparing for two separate NDA submissions following each respective data readout
- In Q2 2025 (one year prior), the trial had only 50 patients enrolled
Financial Impact
No financial data provided in the filing
Risk Factors
- Phase 3 efficacy/safety failure of buntanetap would be a binary negative event
- Cash burn risk given timeline to Q1 2028 disease-modifying readout (no revenue disclosed)
- Regulatory risk — FDA may require additional data beyond the two planned readouts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082341 |
| Document: tm2620172d1_ex99-1.htm | 0001104659-26-082341 |
| Document: 0001104659-26-082341-index-headers.html | 0001104659-26-082341 |
| Document: 0001104659-26-082341-index.html | 0001104659-26-082341 |
| Document: 0001104659-26-082341.txt | 0001104659-26-082341 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 12w ago | 8-K | $1.86 $1.88 | ▲ +1.08% | ▼ −1.35% | $1.18 (−36.56%) |
May 20, 2026 19w ago | 424B5 | $2.15 $1.73 | ▲ +19.53% | ▲ +19.87% | $1.18 (+45.12%) |
May 19, 2026 19w ago | 424B5 | $2.04 $1.75 | ▲ +14.22% | ▲ +14.96% | $1.18 (+42.16%) |
May 15, 2026 20w ago | 8-K | $2.05 $1.79 | ▼ −12.68% | ▼ −14.26% | $1.18 (−42.44%) |
May 15, 2026 20w ago | Press Release | $2.06 $1.78 | ▲ +13.59% | ▲ +15.71% | $1.18 (+42.72%) |
Apr 10, 2026 25w ago | Press Release | $1.59 $2.26 | ▲ +42.14% | ▲ +33.61% | $1.18 (−25.79%) |
Mar 19, 2026 28w ago | Press Release | $2.67 $1.87 | ▼ −29.96% | ▼ −37.58% | $1.18 (−55.81%) |
Mar 16, 2026 28w ago | Press Release | $2.83 $1.73 | ▼ −38.87% | ▼ −42.65% | $1.18 (−58.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access